KRAS Kickers

At @ASCO #GI26 we presented our KRAS KICKERS Trial Finder. Personalized: KRAS G12D, CRC, US trials Results (in 4 minutes): 20 trials go to KRASHUB.ORG in beta - would love your feedback abstract asco.org/abstracts-pres… FYI: G12V - 8 trials for CRC G12R - 7 trials for CRC

Not surprisingly phones are ringing off the hook in cancer centers across the country for expanded access to Daraxonrasib. While @RevMedicines is doing its best to streamline the process, an EAP is not an approval & several steps are involved. reuters.com/legal/litigati…

Really important as the public awareness of Daroxonrasib is so high. NOT all PDAC patients will be eligible for the EAP. "The EAP is intended for patients with previously treated metastatic PDAC who: Are not eligible for participation in a Revolution Medicines-sponsored clinical trial or are unable to access an appropriate clinical trial; and Have no satisfactory alternative treatment options." revmed.com/expanded-acces…

EXPANSION of Daroxonrasib trial May 2026: 5 new sites recruiting (GA, LA, OH, TN, WA) Nov 2025: Phase 1/1b to Phase 1/2 614 to 754 pts Treatment Naive pts allowed NCT05379985 - trial changes #version-content-panel" target="_blank" rel="nofollow noopener">clinicaltrials.gov/study/NCT05379…

Excellent translational work from @BrunaPellini et al. 🔑: resistance after #KRAS #G12C inhibition may create new therapeutic vulnerabilities rather than simply closing doors. 🚪 ‼️ Implications for #ADC combinations, #HER2 assessment in #NSCLC, and post-KRAS inhibitor treatment strategies. Worth reading. 📖 🤔Could adaptive HER2 upregulation become a clinically useful biomarker, or is HER2 scoring in #lungcancer still too variable? 🧬 🫁 @KRASKickers @Exon20Group @LUNGevity #LCSM #KRASG12C @ChristianRolfo

I am grateful to all collaborators who contributed to this work, especially @hilalozakinci @Binadesai14 @AndriyMarusyk who co-lead this work with me and my mentor #EricHaura. These findings helped support the development of my first investigator-initiated clinical trial studying this combination in patients with KRAS G12C-mutant NSCLC. clinicaltrials.gov/study/NCT07012… @drHTBlungpath @Hitendras08 @KRASKickers @BaptistHealthSF @MiamiCancerInst @BHCancerCare @MoffittNews @MoffittResearch

🚨New Pub 🧵1) Our new study in #TranslationalLungCancerResearch explores a combination strategy for #KRASG12C-mutant #NSCLC: sotorasib plus trastuzumab deruxtecan. In preclinical models, the combination produced deeper and more durable regressions than either agent alone. tlcr.amegroups.org/article/view/1…

3)We also observed adaptive HER2 upregulation with KRAS inhibition, which may help explain why this combination showed stronger activity in that setting. At the same time, our patient sample analysis highlighted how complex HER2 assessment remains in lung cancer

Wonderful visit from @TheVinodLab from @MSKCancerCenter, delivering a fantastic talk on the future of pancreatic cancer and vaccines 💉 Truly revolutionary, groundbreaking science 🧬 Pancreas cancer, watch out, we’re coming for you 💜 @FoxChaseCancer @PanCAN @PanCANPhilly

Great to be able to learn regulatory policy directly from @US_FDA leaders, especially right now with a breakthrough in PDAC treatment under FDA evaluation. Thank you to @AACR for making this program possible.

Pancreatic cancer is one of the most dire diagnoses in medicine with few available treatments. Until now, thanks to university research, including @UCSF scientists, and federal investment in science research. Read about this huge breakthrough via @nytimes nyti.ms/4wfziXs

@DavidHongMD Yes! As has been noted... and shared with patient groups! Still so many people looking for trial options.

Ditto we have it open and then some!

This April, we got a drug revolutionary in 3 ways: daraxonrasib roughly doubles survival in metastatic pancreatic cancer, cracked RAS, a protein deemed untreatable for decades & pioneered a drug class called molecular glues. Read more in my piece @WorksInProgMag worksinprogress.news/p/pancreatic-c… - Pancreatic cancer is a particularly tough cancer. - It's diagnosed late in its progression and it coats itself with tissue that block the immune system from attacking it. This makes immunotherapies, which have been revolutionary in other metastatic cancers (e.g. melanoma) ineffective against it. - 90% of pancreatic cancer have one mutated protein: RAS. This should make it easily targetable. But ... not so quick! - RAS has a property that has made it "undruggable" for decades: it largely lacks the pockets or grooves that most drugs depend on to bind and act upon their target. - Molecular glues sidestep the problem entirely. Instead of binding a pocket, daraxonrasib forces two proteins together — locking RAS in its inactive state by wedging a third protein in the way. - The result: median survival of 13.2 months vs ~6 on standard chemo. Not a cure, but a genuine doubling, delivered as a daily pill. - The implications go far beyond pancreatic cancer. RAS is mutated in lung, colorectal, and many other cancers. Molecular glues are now being developed against multiple other "undruggable" targets. The assumption that certain proteins are simply beyond reach has turned out, repeatedly, to be wrong. - The bad news is that most patients eventually develop resistance mutations that vary from patient to patient. In order to deliver a real cure, we need to rethink our regulatory system and make small-n, early stage bespoke trials much easier to run.

expansion to Mass General KST-6051

How an ‘Impossible’ Idea Led to a #PancreaticCancer Breakthrough nytimes.com/2026/05/12/hea… I still remember my conversation with @cjder23 at an @AACR meeting a few years ago - shocked at how well tolerated Daraxonrasib was given all RAS isoforms, including wild type, was shut down.

Science behind the Study: Advances in RAS Therapeutics for Pancreatic Cancer nej.md/4neOTCE #Oncology #Gastroenterology

One week ago today.

I have a patient with glioblastoma who got halfway through a clinical trial and was seeing great results, only to have his treatment ceased when the trial stopped. He then spent $10,000 of his own money trying to use Expanded Access, and was denied. Now, accessing treatment through Montana's SB535 is his last hope. There are biotechs and manufacturers willing to provide treatment, but only if we can get guarantees they won't be punished by @US_FDA for doing so. I'll be in Washington D.C. with him on the 19th and 20th of this month, if anyone reading this would like to help, please tag your Senator and House Rep and ask them to make some time to meet with us.

looking forward to the KRAS Initiative! @Aiims1742

An experimental pancreatic cancer drug that’s been shown to double survival in patients with advanced stages of the disease is poised to revolutionize the way the cancer is treated, oncologists say. nbcnews.com/health/health-…

A Phase 1, Open-label Dose Escalation and Expansion Study of PT0511 in Participants With KRAS Mutated OR Amplified Advanced Solid Tumors pan-KRAS degrader Phase 1 trial 5 US locations (3 just opened for enrollment) 195 patients, multiple tumor types Opened Nov 2025 NCT07300150 clinicaltrials.gov/study/NCT07300…